[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100484623":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":33,"locations":41,"responsibleParty":98,"collaborators":18,"id":100,"slug":101,"hasResults":102,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":102,"sex":108,"minAge":109,"maxAge":18,"enrollmentInfo":110,"targetDuration":18,"studyType":113,"phases":114,"briefSummary":116,"conditions":117,"keywords":18,"overallStatus":44,"whyStopped":18,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},{"fullName":5,"class":6},"ANRS, Emerging Infectious Diseases","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Adalimumab arm","EXPERIMENTAL","* Standard TBM treatment\n* Adalimumab 40 mg: one sub-cutaneous injection, every 2 weeks for 10 weeks (total 6 injections), started as soon as possible during the first 3 days of antituberculosis treatment and high-dose steroids",[13],"Drug: Adalimumab Injection",{"label":15,"type":16,"description":17,"interventionNames":18},"Control arm","NO_INTERVENTION","\\- Standard TBM",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Adalimumab Injection","one sub-cutaneous injection, every 2 weeks for 10 weeks (total 6 injections), started as soon as possible during the first 3 days of antituberculosis treatment and high-dose steroids",[9],[26,30],{"name":27,"affiliation":28,"role":29},"Nathalie DE CASTRO, MD","AP-HP, Hôpital Saint-Louis","PRINCIPAL_INVESTIGATOR",{"name":31,"affiliation":32,"role":29},"Celso KHOSA, MD","Instituto Nacional de Saúde, Mozambique",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":18,"email":38},"Vanessa MACHAULT, PhD","CONTACT","+335 57 57 57 63","vanessa.machault@u-bordeaux.fr",{"name":40,"role":36,"phone":18,"phoneExt":18,"email":18},"Olivier MARCY, MD PhD",[42,62,79],{"facility":43,"status":44,"city":45,"state":18,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Laboratory of clinical research on STD\u002FAIDS - IPEC\u002FFIOCRUZ","RECRUITING","Rio de Janeiro","21040-900","Brazil","BR",{"type":50,"coordinates":51},"Point",[52,53],-43.18223,-22.90642,{"lat":53,"lon":52},[56,60],{"name":57,"role":36,"phone":58,"phoneExt":18,"email":59},"Sandra WAGNER","+ 55 21 38 65 96 23","dra.wagner@gmail.com",{"name":61,"role":29,"phone":18,"phoneExt":18,"email":18},"Beatriz GRINSZTEJN",{"facility":63,"status":64,"city":65,"state":18,"zip":18,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Instituto Nacional de Saude","NOT_YET_RECRUITING","Maputo","Mozambique","MZ",{"type":50,"coordinates":69},[70,71],32.58322,-25.96553,{"lat":71,"lon":70},[74,77],{"name":75,"role":36,"phone":18,"phoneExt":18,"email":76},"Marcia CHILUVANE","marcia.chiluvane@ins.gov.mz",{"name":78,"role":29,"phone":18,"phoneExt":18,"email":18},"Celso KHOSA",{"facility":80,"status":64,"city":81,"state":18,"zip":18,"country":82,"countryCode":83,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Adult Infectious Diseases Centre, University Teaching Hospital","Lusaka","Zambia","ZM",{"type":50,"coordinates":85},[86,87],28.28713,-15.40669,{"lat":87,"lon":86},[90,93,96],{"name":91,"role":36,"phone":18,"phoneExt":18,"email":92},"Christabel Phiri","chigweyassin@gmail.com",{"name":94,"role":36,"phone":18,"phoneExt":18,"email":95},"Seke Muzazu","sekemuzazu@gmail.com",{"name":97,"role":29,"phone":18,"phoneExt":18,"email":18},"Ducan CHANDA",{"type":99,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100484623","phase-2-tnf-inhibitors-to-reduce-mortality-in-hiv-1-infected-patients-with-tuberculosis-meningitis-100484623",false,"NCT05590455","Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis","ANRS 12404 TIMPANI: Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis: a Phase II, Multicenter, Randomized Clinical Trial","TIMPANI","Inclusion Criteria:\n\n* Age ≥18 years\n* HIV-1 infection\n* Definite or probable tuberculosis meningitis\n* Standard tuberculosis meningitis treatment ≤3 days: anti TB drugs at standard doses and high-dose dexamethasone as per WHO guidelines\n* Signed informed consent form by patient or relative.\n\nExclusion Criteria:\n\n* Other concomitant neurological infection, i.e. toxoplasmosis, cryptococcosis, progressive multifocal leukoencephalopathy, bacterial meningitis, neuro-syphilis\n* Asymptomatic positive cryptococcal antigen in serum\n* HBsAg positive or anti hepatitis C virus antibodies positive\n* Alanine transaminase (ALT)\\>5 ULN\n* Rifampicin-resistant TB detected by GeneXpert MTB\u002FRIF Ultra\n* History of previous TB treatment in patients with GeneXpert MTB\u002FRIF Ultra negative or unavailable\n* Current use of drugs contraindicated with study drugs and that cannot be safely stopped\n* Allergy to study drugs or any of their components\n* Uncontrolled opportunistic infection\n* Moderate to severe cardiac insufficiency (NYHA classes III \u002F IV)\n* Any condition which might, in the investigator's opinion, compromise the safety of treatment and\u002For patient's adherence to study procedures\n* For women of childbearing age: 1) Pregnancy or breastfeeding; 2) Refusal to use effective contraception to be discussed with the investigator\n* Subjects participating in another clinical trial evaluating therapies and including an exclusion period that is still in force during the screening phase\n* Person under guardianship, or deprived of freedom by a judicial or administrative decision","ALL","18 Years",{"count":111,"type":112},130,"ESTIMATED","INTERVENTIONAL",[115],"PHASE2","Randomized phase II clinical trial which aims to assess the impact on 3-month mortality and safety of adding adalimumab to standard treatment (anti-tuberculosis drugs and corticosteroids) in HIV patients with tuberculosis meningitis in 3 countries (Brazil, Mozambique, and Zambia).",[118,119],"Tuberculous Meningitis","HIV I Infection","2025-12-08",{"date":122,"type":123},"2025-12-15","ACTUAL",{"date":125,"type":123},"2023-04-11",{"date":127,"type":112},"2027-12",{"name":5,"class":6},3]